The latest biotech news

News and Trends 2 May 2017

Entrepreneurs, Academics & Entrepreneurial Academics succeed in Berlin

With Berlin’s plethora of life science research and academia, opportunities abound for biotech entrepreneurs. Here’s how the city bridges the gap between science and business! So much research, so many opportunities for academics and entrepreneurs. Berlin boasts 35 large research institutions focused on life sciences, and around 130 hospitals — including Europe’s largest and most […]

May 2, 2017 - 5 minutesmins - By External Contributor

News and Trends 29 Apr 2017

These Bioartists Turn Cell-to-Cell Communication in your Body into Sound

Thought Collider and David Young have developed an installation that transforms the faint communication signals between your skin cells into sounds. Artist duo Thought Collider is comprised of Mike Thompson, from the UK, and Susana Cámara Leret, from Spain. Based in Amsterdam and London, they experiment with the living nature of our bodies and microorganisms. Their […]

April 29, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Apr 2017

The Tires of the Future will be made with… Dandelions?

Continental, famous producer of tires, is creating a research facility in Germany to investigate the use of rubber extracted from dandelions. An eventual switch to the material would mean less environmental impact, and maybe even better tires. The “green pet project” of Continental, a giant automotive manufacturer with almost €40Bn yearly revenues, consists of replacing conventional natural […]

April 28, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 27 Apr 2017

Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation

Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into the mechanism of action of antagonists of the protease-activated receptor 2 (PAR2), a molecule involved in metabolism and inflammatory responses. The study is part of […]

April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Apr 2017

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, […]

April 26, 2017 - 1 minutemin - By Melanie De Almeida

News and Trends 25 Apr 2017

Novartis Negotiates its Way into the US Migraine Market

Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed their second Phase III study for their migraine drug erenumab, the companies have now reworked their commercial partnership. The two pharma giants teamed up back in 2015 to co-develop […]

April 25, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 25 Apr 2017

EMA designates uniQure’s gene therapy for hemophilia a priority

Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial failure, uniQure has been on the rebound. The company recently has undergone several management shakeups and a strategy review, and it just made the decision to withdraw […]

April 25, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 25 Apr 2017

New Research could Save Patients from Graft-Versus-Host Disease

A new study published in the journal Science Translational Medicine identifies a new treatment strategy to prevent GVHD after stem cell transplantation. Allogeneic stem cell transplantation remains one of the top treatments for blood cancers and inherited blood disorders, but the treatment is associated with a major risk of so-called graft-versus-host disease (GVHD). A new paper […]

April 25, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 24 Apr 2017

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […]

April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Apr 2017

Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance

Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […]

April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Apr 2017

The World’s Most Expensive Drugs have European Owners

A new report has listed the world’s most expensive drugs. Not surprisingly, those targeting rare diseases bear the heaviest price tags – let’s have a look. While biotechs like Généthon and EspeRare are rethinking the high-risk high-profit model and looking to provide treatments at an affordable price, most rare disease meds on the market are among the most […]

April 21, 2017 - 4 minutesmins - By Melanie De Almeida

fungi secondary metabolites genome sequencing

News and Trends 21 Apr 2017

Fungi Genomes could be a Gold Mine of New Antibiotics

Good old Penicillium still has a lot more tricks upon its sleeve: Swedish researchers see its potential as a gold mine for new antibiotics. The genomic analysis of Penicillium species represents a potential gold mine for new bioactive compounds, or improved versions of those we already use. Published recently in Nature Microbiology, the work was carried at Chalmers University […]

April 21, 2017 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Entrepreneurs, Academics & Entrepreneurial Academics succeed in Berlin

These Bioartists Turn Cell-to-Cell Communication in your Body into Sound

The Tires of the Future will be made with… Dandelions?

Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Novartis Negotiates its Way into the US Migraine Market

EMA designates uniQure’s gene therapy for hemophilia a priority

New Research could Save Patients from Graft-Versus-Host Disease

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance

The World’s Most Expensive Drugs have European Owners

Fungi Genomes could be a Gold Mine of New Antibiotics

Subscribe to our newsletter to get the latest biotech news!